Ultragenyx Pharmaceutical (RARE) EPS (Weighted Average and Diluted) Growth (1y) (2018 - 2026)
Ultragenyx Pharmaceutical (RARE) EPS (Weighted Average and Diluted) Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 251.11% |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 102.51% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -79.34% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -103.05% |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 61.45% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ultragenyx Pharmaceutical | 2.77 Bn | 2.36 Bn | 106.00 Mn | -17.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.20% |
| Dec 31, 2025 | 7.25% |
| Sep 30, 2025 | -29.29% |
| Jun 30, 2025 | 23.03% |
| Mar 31, 2025 | 22.66% |
| Dec 31, 2024 | 4.17% |
| Sep 30, 2024 | 37.22% |
| Jun 30, 2024 | 32.44% |
| Mar 31, 2024 | 12.88% |
| Dec 31, 2023 | 33.33% |
| Sep 30, 2023 | 36.29% |
| Jun 30, 2023 | 0.44% |
| Mar 31, 2023 | -6.39% |
| Dec 31, 2022 | -20.67% |
| Sep 30, 2022 | -224.07% |
| Jun 30, 2022 | -24.86% |
| Dec 31, 2021 | -353.60% |
| Jun 30, 2021 | -541.46% |
| Mar 31, 2019 | -393.55% |
| Mar 31, 2018 | 138.04% |